News: AEterna Zentaris, Inc. (AEZ.TO)
0.93CAD
16 Dec 2009
$0.03 (+3.33%)
$0.90
$0.90
$0.94
$0.89
58,530
188,304
$3.49
$0.50
Mon, Dec 7 2009
UPDATE 2-Aeterna's prostate treatment misses key goal
TORONTO, Dec 7 (Reuters) - Aeterna Zentaris Inc's treatment for enlarged prostate missed key goals in a European study, the drugmaker said on Monday, raising more doubts that the treatment will win regulatory approval and sending the company's shares tumbling.
BEFORE THE BELL-AEterna shares drop after study misses target
NEW YORK, Dec 7 (Reuters) - AEterna Zentaris Inc shares tumbled 28.6 percent to 80 cents on Monday after the company said its European phase 3 study with Cetrorelix in benign prostatic hyperplasia missed its primary endpoint. [ID:nWNBB8600]
UPDATE 2-FDA fast tracks Aeterna, Keryx cancer drug
* Aeterna shares up 7.6 pct, Keryx shares up 9.4 pct (Adds analyst's comments. In U.S. dollars)
CANADA STOCKS-TSX drops on commodity weakness, U.S. data
* U.S. Q3 GDP revision slightly lower than expected (Adds details)
UPDATE 2-Aeterna stock jumps, ebbs after cancer trial data
* Shares pare gains after analysts downplay data (Adds details, analyst comment)
BEFORE THE BELL-AEterna Zentaris jumps after drug trial results
NEW YORK, Nov 24 (Reuters) - AEterna Zentaris Inc shares jumped 21.2 percent to $1.20 in premarket trade on Tuesday after the company said its endometrial cancer drug met its primary goal in a midstage trial. [ID:nWNAB9283]
UPDATE 1-Aeterna Zentaris narrows Q3 loss
Nov 11 (Reuters) - Canadian biopharmaceuticals company Aeterna Zentaris Inc narrowed its third-quarter loss, helped by lower research and development expenses.
Aeterna stock jumps on early cancer drug test
TORONTO (Reuters) - Aeterna Zentaris said on Monday that Phase 1 results for its cancer tumor treatment caused little side effects in patients and proved that it could work with other cancer treatments, sending the drugmaker's shares up more than 15 percent.
UPDATE 1-Keryx cancer drug gets orphan drug status; shares soar
* Keryx shares up as much as 72 pct * Shares of Aeterna Zentaris up as much as 36 pct Sept 16 (Reuters) - Keryx Biopharmaceuticals Inc said its experimental cancer drug, KRX-0401, received orphan drug designation from U.S. health regulators, sending its shares up to a new 52-week high.
CANADA STOCKS-TSX may open higher on firming commodities, hope
TORONTO, Aug 24 (Reuters) - Toronto's main stock index may head higher at the open on Monday as firm commodity prices buoy the resource-heavy index, while reassurances from world central bankers spurred optimism about the world's economic recovery.
Press Releases
- Æterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
- AEterna Zentaris Announces Appointment of New Board Member
- AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hemat
- Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematol
- AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
